Does the media refer more to ZVRA or IRON?

In the previous week, Disc Medicine had 7 more articles in the media than Zevra Therapeutics. MarketBeat recorded 16 mentions for Disc Medicine and 9 mentions for Zevra Therapeutics. Disc Medicine's average media sentiment score of 0.57 beat Zevra Therapeutics' score of 0.03 indicating that Disc Medicine is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zevra Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Disc Medicine 5 Very Positive mention(s) 0 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate ZVRA or MOR?

Zevra Therapeutics currently has a consensus price target of $26.86, indicating a potential upside of 182.41%. Given Zevra Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Zevra Therapeutics is more favorable than MorphoSys. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zevra Therapeutics 0 Sell rating(s) 2 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.82 MorphoSys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is ZVRA or MOR more profitable?

Zevra Therapeutics has a net margin of 101.58% compared to MorphoSys' net margin of -226.79%. Zevra Therapeutics' return on equity of 51.49% beat MorphoSys' return on equity. Company Net Margins Return on Equity Return on Assets Zevra Therapeutics 101.58% 51.49% 28.86% MorphoSys -226.79% -694.31% -22.55%

Do analysts rate ZVRA or RGC?

Zevra Therapeutics currently has a consensus price target of $26.86, suggesting a potential upside of 182.41%. Given Zevra Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Zevra Therapeutics is more favorable than Regencell Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zevra Therapeutics 0 Sell rating(s) 2 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.82 Regencell Bioscience 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation and earnings, ZVRA or RGC?

Zevra Therapeutics has higher revenue and earnings than Regencell Bioscience. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zevra Therapeutics $122.29M 4.60 $83.23M $1.99 4.78 Regencell Bioscience N/A N/A -$3.58M N/A N/A

Does the media prefer BEAM or ZVRA?

In the previous week, Beam Therapeutics had 2 more articles in the media than Zevra Therapeutics. MarketBeat recorded 11 mentions for Beam Therapeutics and 9 mentions for Zevra Therapeutics. Beam Therapeutics' average media sentiment score of 1.06 beat Zevra Therapeutics' score of 0.03 indicating that Beam Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beam Therapeutics 7 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zevra Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to ZVRA or RARE?

In the previous week, Zevra Therapeutics had 2 more articles in the media than Ultragenyx Pharmaceutical. MarketBeat recorded 9 mentions for Zevra Therapeutics and 7 mentions for Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical's average media sentiment score of 0.86 beat Zevra Therapeutics' score of 0.03 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zevra Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Ultragenyx Pharmaceutical 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Zevra Therapeutics (ZVRA) Competitors

$9.51 0.00 (0.00%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$9.60 +0.09 (+0.89%)

As of 07/31/2026 07:46 PM Eastern

Compare

ZVRA vs. IRON, MOR, RGC, BEAM, and RARE

Should you buy Zevra Therapeutics stock or one of its competitors? MarketBeat compares Zevra Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Zevra Therapeutics include Disc Medicine (IRON), MorphoSys (MOR), Regencell Bioscience (RGC), Beam Therapeutics (BEAM), and Ultragenyx Pharmaceutical (RARE).

How does Zevra Therapeutics compare to Disc Medicine?

Zevra Therapeutics (NASDAQ:ZVRA) and Disc Medicine (NASDAQ:IRON) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, earnings, media sentiment, risk, dividends and valuation.

In the previous week, Disc Medicine had 7 more articles in the media than Zevra Therapeutics. MarketBeat recorded 16 mentions for Disc Medicine and 9 mentions for Zevra Therapeutics. Disc Medicine's average media sentiment score of 0.57 beat Zevra Therapeutics' score of 0.03 indicating that Disc Medicine is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zevra Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Disc Medicine	5 Very Positive mention(s)	0 Positive mention(s)	10 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Zevra Therapeutics presently has a consensus price target of $26.86, suggesting a potential upside of 182.41%. Disc Medicine has a consensus price target of $104.44, suggesting a potential upside of 35.64%. Given Zevra Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Zevra Therapeutics is more favorable than Disc Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zevra Therapeutics	0 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.82
Disc Medicine	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

Zevra Therapeutics has a net margin of 101.58% compared to Disc Medicine's net margin of 0.00%. Zevra Therapeutics' return on equity of 51.49% beat Disc Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zevra Therapeutics	101.58%	51.49%	28.86%
Disc Medicine	N/A	-37.17%	-33.65%

35.0% of Zevra Therapeutics shares are held by institutional investors. Comparatively, 83.7% of Disc Medicine shares are held by institutional investors. 2.4% of Zevra Therapeutics shares are held by company insiders. Comparatively, 3.8% of Disc Medicine shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Zevra Therapeutics has a beta of 0.85, indicating that its stock price is 15% less volatile than the broader market. Comparatively, Disc Medicine has a beta of 1, indicating that its stock price has a similar volatility profile to the broader market.

Zevra Therapeutics has higher revenue and earnings than Disc Medicine. Disc Medicine is trading at a lower price-to-earnings ratio than Zevra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zevra Therapeutics	$122.29M	4.60	$83.23M	$1.99	4.78
Disc Medicine	N/A	N/A	-$212.18M	-$6.58	N/A

Summary

Zevra Therapeutics beats Disc Medicine on 9 of the 14 factors compared between the two stocks.

How does Zevra Therapeutics compare to MorphoSys?

Zevra Therapeutics (NASDAQ:ZVRA) and MorphoSys (NASDAQ:MOR) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, profitability, analyst recommendations, institutional ownership and media sentiment.

In the previous week, Zevra Therapeutics had 9 more articles in the media than MorphoSys. MarketBeat recorded 9 mentions for Zevra Therapeutics and 0 mentions for MorphoSys. Zevra Therapeutics' average media sentiment score of 0.03 beat MorphoSys' score of 0.00 indicating that Zevra Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Zevra Therapeutics	Neutral
MorphoSys	Neutral

Zevra Therapeutics has a net margin of 101.58% compared to MorphoSys' net margin of -226.79%. Zevra Therapeutics' return on equity of 51.49% beat MorphoSys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zevra Therapeutics	101.58%	51.49%	28.86%
MorphoSys	-226.79%	-694.31%	-22.55%

Zevra Therapeutics has a beta of 0.85, indicating that its share price is 15% less volatile than the broader market. Comparatively, MorphoSys has a beta of 1.2, indicating that its share price is 20% more volatile than the broader market.

Zevra Therapeutics has higher earnings, but lower revenue than MorphoSys. MorphoSys is trading at a lower price-to-earnings ratio than Zevra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zevra Therapeutics	$122.29M	4.60	$83.23M	$1.99	4.78
MorphoSys	$238.28M	11.99	-$205.35M	-$3.48	N/A

35.0% of Zevra Therapeutics shares are owned by institutional investors. Comparatively, 18.4% of MorphoSys shares are owned by institutional investors. 2.4% of Zevra Therapeutics shares are owned by company insiders. Comparatively, 0.1% of MorphoSys shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Zevra Therapeutics currently has a consensus price target of $26.86, indicating a potential upside of 182.41%. Given Zevra Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Zevra Therapeutics is more favorable than MorphoSys.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zevra Therapeutics	0 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.82
MorphoSys	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Zevra Therapeutics beats MorphoSys on 13 of the 16 factors compared between the two stocks.

How does Zevra Therapeutics compare to Regencell Bioscience?

Zevra Therapeutics (NASDAQ:ZVRA) and Regencell Bioscience (NASDAQ:RGC) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, analyst recommendations, valuation, profitability, earnings, dividends and media sentiment.

Zevra Therapeutics currently has a consensus price target of $26.86, suggesting a potential upside of 182.41%. Given Zevra Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Zevra Therapeutics is more favorable than Regencell Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zevra Therapeutics	0 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.82
Regencell Bioscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

35.0% of Zevra Therapeutics shares are owned by institutional investors. Comparatively, 0.1% of Regencell Bioscience shares are owned by institutional investors. 2.4% of Zevra Therapeutics shares are owned by insiders. Comparatively, 2.0% of Regencell Bioscience shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Zevra Therapeutics had 9 more articles in the media than Regencell Bioscience. MarketBeat recorded 9 mentions for Zevra Therapeutics and 0 mentions for Regencell Bioscience. Zevra Therapeutics' average media sentiment score of 0.03 beat Regencell Bioscience's score of 0.00 indicating that Zevra Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Zevra Therapeutics	Neutral
Regencell Bioscience	Neutral

Zevra Therapeutics has a beta of 0.85, indicating that its share price is 15% less volatile than the broader market. Comparatively, Regencell Bioscience has a beta of 1.84, indicating that its share price is 84% more volatile than the broader market.

Zevra Therapeutics has higher revenue and earnings than Regencell Bioscience.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zevra Therapeutics	$122.29M	4.60	$83.23M	$1.99	4.78
Regencell Bioscience	N/A	N/A	-$3.58M	N/A	N/A

Zevra Therapeutics has a net margin of 101.58% compared to Regencell Bioscience's net margin of 0.00%. Zevra Therapeutics' return on equity of 51.49% beat Regencell Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zevra Therapeutics	101.58%	51.49%	28.86%
Regencell Bioscience	N/A	N/A	N/A

Summary

Zevra Therapeutics beats Regencell Bioscience on 12 of the 13 factors compared between the two stocks.

How does Zevra Therapeutics compare to Beam Therapeutics?

Beam Therapeutics (NASDAQ:BEAM) and Zevra Therapeutics (NASDAQ:ZVRA) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, valuation, earnings and dividends.

99.7% of Beam Therapeutics shares are held by institutional investors. Comparatively, 35.0% of Zevra Therapeutics shares are held by institutional investors. 3.8% of Beam Therapeutics shares are held by insiders. Comparatively, 2.4% of Zevra Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Zevra Therapeutics has a net margin of 101.58% compared to Beam Therapeutics' net margin of -39.66%. Zevra Therapeutics' return on equity of 51.49% beat Beam Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beam Therapeutics	-39.66%	-29.00%	-22.61%
Zevra Therapeutics	101.58%	51.49%	28.86%

Zevra Therapeutics has lower revenue, but higher earnings than Beam Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than Zevra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beam Therapeutics	$164.01M	16.01	-$79.99M	-$0.68	N/A
Zevra Therapeutics	$122.29M	4.60	$83.23M	$1.99	4.78

Beam Therapeutics has a beta of 2.18, meaning that its share price is 118% more volatile than the broader market. Comparatively, Zevra Therapeutics has a beta of 0.85, meaning that its share price is 15% less volatile than the broader market.

Beam Therapeutics presently has a consensus target price of $46.85, suggesting a potential upside of 83.57%. Zevra Therapeutics has a consensus target price of $26.86, suggesting a potential upside of 182.41%. Given Zevra Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Zevra Therapeutics is more favorable than Beam Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beam Therapeutics	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.64
Zevra Therapeutics	0 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.82

In the previous week, Beam Therapeutics had 2 more articles in the media than Zevra Therapeutics. MarketBeat recorded 11 mentions for Beam Therapeutics and 9 mentions for Zevra Therapeutics. Beam Therapeutics' average media sentiment score of 1.06 beat Zevra Therapeutics' score of 0.03 indicating that Beam Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Beam Therapeutics	7 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zevra Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Beam Therapeutics and Zevra Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Zevra Therapeutics compare to Ultragenyx Pharmaceutical?

Zevra Therapeutics (NASDAQ:ZVRA) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, institutional ownership, analyst recommendations, risk, profitability and earnings.

35.0% of Zevra Therapeutics shares are held by institutional investors. Comparatively, 97.7% of Ultragenyx Pharmaceutical shares are held by institutional investors. 2.4% of Zevra Therapeutics shares are held by company insiders. Comparatively, 5.2% of Ultragenyx Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Zevra Therapeutics has a net margin of 101.58% compared to Ultragenyx Pharmaceutical's net margin of -91.03%. Zevra Therapeutics' return on equity of 51.49% beat Ultragenyx Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zevra Therapeutics	101.58%	51.49%	28.86%
Ultragenyx Pharmaceutical	-91.03%	-1,024.42%	-45.78%

Zevra Therapeutics presently has a consensus price target of $26.86, indicating a potential upside of 182.41%. Ultragenyx Pharmaceutical has a consensus price target of $58.41, indicating a potential upside of 134.49%. Given Zevra Therapeutics' higher probable upside, research analysts clearly believe Zevra Therapeutics is more favorable than Ultragenyx Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zevra Therapeutics	0 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.82
Ultragenyx Pharmaceutical	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.83

Zevra Therapeutics has a beta of 0.85, indicating that its share price is 15% less volatile than the broader market. Comparatively, Ultragenyx Pharmaceutical has a beta of 0.35, indicating that its share price is 65% less volatile than the broader market.

Zevra Therapeutics has higher earnings, but lower revenue than Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical is trading at a lower price-to-earnings ratio than Zevra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zevra Therapeutics	$122.29M	4.60	$83.23M	$1.99	4.78
Ultragenyx Pharmaceutical	$673M	3.65	-$575M	-$6.11	N/A

In the previous week, Zevra Therapeutics had 2 more articles in the media than Ultragenyx Pharmaceutical. MarketBeat recorded 9 mentions for Zevra Therapeutics and 7 mentions for Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical's average media sentiment score of 0.86 beat Zevra Therapeutics' score of 0.03 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zevra Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ultragenyx Pharmaceutical	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Zevra Therapeutics beats Ultragenyx Pharmaceutical on 10 of the 17 factors compared between the two stocks.

Get Zevra Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZVRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ZVRA vs. The Competition

Export

Metric	Zevra Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$562.18M	$11.72B	$6.85B	$12.42B
Dividend Yield	N/A	2.72%	2.59%	10.03%
P/E Ratio	4.78	799.05	282.30	24.66
Price / Sales	4.60	753.67	564.25	75.48
Price / Cash	10.05	14.82	28.60	46.71
Price / Book	3.46	10.35	10.98	6.07
Net Income	$83.23M	$2.82B	$3.49B	$347.99M
7 Day Performance	-2.06%	-0.10%	-0.60%	-0.44%
1 Month Performance	-31.97%	-3.95%	-5.19%	-4.81%
1 Year Performance	-14.40%	156.15%	62.02%	18.61%

Zevra Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ZVRA Zevra Therapeutics	4.0957 of 5 stars	$9.51 flat	$26.86 +182.4%	-14.4%	$562.18M	$122.29M	4.78	20	Upcoming Earnings
IRON Disc Medicine	2.206 of 5 stars	$74.12 -2.3%	$104.44 +40.9%	+30.6%	$2.89B	N/A	N/A	30	Earnings Report Upcoming Earnings Analyst Upgrade
MOR MorphoSys	N/A	$18.96 flat	N/A	N/A	$2.86B	$238.28M	N/A	730
RGC Regencell Bioscience	0.1028 of 5 stars	$5.72 +1.8%	N/A	-52.4%	$2.78B	N/A	N/A	10	Gap Down
BEAM Beam Therapeutics	2.5419 of 5 stars	$25.10 -3.1%	$46.85 +86.6%	+35.5%	$2.67B	$164.01M	N/A	510	News Coverage Positive News Upcoming Earnings Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ZVRA) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Zevra Therapeutics (ZVRA) Competitors

ZVRA vs. IRON, MOR, RGC, BEAM, and RARE

How does Zevra Therapeutics compare to Disc Medicine?

Summary

How does Zevra Therapeutics compare to MorphoSys?

Summary

How does Zevra Therapeutics compare to Regencell Bioscience?

Summary

How does Zevra Therapeutics compare to Beam Therapeutics?

Summary

How does Zevra Therapeutics compare to Ultragenyx Pharmaceutical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZVRA vs. The Competition

Zevra Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Zevra Therapeutics (ZVRA) Competitors

ZVRA vs. IRON, MOR, RGC, BEAM, and RARE

How does Zevra Therapeutics compare to Disc Medicine?

Does the media refer more to ZVRA or IRON?

Do analysts rate ZVRA or IRON?

Is ZVRA or IRON more profitable?

Do institutionals & insiders have more ownership in ZVRA or IRON?

Which has more risk & volatility, ZVRA or IRON?

Which has better earnings and valuation, ZVRA or IRON?

Summary

How does Zevra Therapeutics compare to MorphoSys?

Does the media refer more to ZVRA or MOR?

Is ZVRA or MOR more profitable?

Which has more risk and volatility, ZVRA or MOR?

Which has preferable earnings and valuation, ZVRA or MOR?

Do institutionals and insiders believe in ZVRA or MOR?

Do analysts rate ZVRA or MOR?

Summary

How does Zevra Therapeutics compare to Regencell Bioscience?

Do analysts rate ZVRA or RGC?

Do insiders & institutionals hold more shares of ZVRA or RGC?

Does the media favor ZVRA or RGC?

Which has more risk and volatility, ZVRA or RGC?

Which has better valuation and earnings, ZVRA or RGC?

Is ZVRA or RGC more profitable?

Summary

How does Zevra Therapeutics compare to Beam Therapeutics?

Do institutionals & insiders have more ownership in BEAM or ZVRA?

Is BEAM or ZVRA more profitable?

Which has higher valuation & earnings, BEAM or ZVRA?

Which has more volatility & risk, BEAM or ZVRA?

Do analysts rate BEAM or ZVRA?

Does the media prefer BEAM or ZVRA?

Summary

How does Zevra Therapeutics compare to Ultragenyx Pharmaceutical?

Do institutionals and insiders believe in ZVRA or RARE?

Is ZVRA or RARE more profitable?

Do analysts rate ZVRA or RARE?

Which has more volatility and risk, ZVRA or RARE?

Which has better valuation & earnings, ZVRA or RARE?

Does the media refer more to ZVRA or RARE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZVRA vs. The Competition

Zevra Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools